spottrends.blogg.se - Monkey strong together

Monkey strong together professional#

The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended key risk groups for vaccination against mpox to support states and territories to prioritise their supply. State and territories will provide further advice on how the vaccine can be accessed within their jurisdiction. These decisions will be informed by local risk factors, such as local outbreaks and vaccine supply.

This includes how and where it will be available and who will be prioritised to receive the vaccine.

States and territories are responsible for administration of the vaccine in their jurisdiction.

People whose occupations might put them at increased risk, including laboratory staff and healthcare workers.

Population groups who might be at higher risk of exposure or further transmission, such as gay, bisexual, or other men who have sex with men who have a high number of sexual contacts or are travelling to countries where mpox is present, or those where mpox is more likely to result in serious illness.

Close physical contacts of people infected with mpox, such as intimate partners and people who live in the same household.

Given vaccine supply is limited, access to vaccines will initially be prioritised to support strong outbreak management, and this may include those who are: The Australian Government, in conjunction with states and territories, has secured an initial supply of JYNNEOS® and is working with the manufacturer to secure more. There is a globally limited supply of the JYNNEOS® vaccine and high international demand. Visit the TGA website for more consumer information and product information about ACAM2000™.

people with cardiac disease or cardiac risk factorsĪCAM2000™ is registered with the Therapeutic Goods Administration (TGA) for use in Australia.

people who are pregnant or breastfeeding.

ACAM2000™ is manufactured by Emergent BioSolutions.Īdministration of ACAM2000™ requires specialised training and facilities. ACAM2000™ vaccineĪCAM2000™ is a live-attenuated smallpox vaccine that is also effective against mpox. JYNNEOS® is registered with both the US Food and Drug Administration and the European Medicines Agency.įurther information is available in the JYNNEOS® vaccine information sheet. The Therapeutic Goods Administration has and will continue to review available information about quality and safety of JYNNEOS®, including reported adverse events and data provided by international regulators. This pathway ensures that vaccine is available urgently to deal emergencies and critical threats to public health. The Australian Government has made JYNNEOS® available immediately via a special emergency pathway under section 18A of the Therapeutic Goods Act 1989.

It is also not preferred as a first dose for post-exposure vaccination. However, intradermal administration of this vaccine is not recommended for anyone with a weakened immune system or a history of keloid scarring. JYNNEOS® can be injected subcutaneously (under the skin, preferably into the upper arm) or intradermally (into the outer layers of skin). The Australian Technical Advisory Group on Immunisation (ATAGI) has advised that that vaccination with JYNNEOS® in children can be considered, especially for people in high-risk groups aged 16 years and older, after discussing the risks and benefits with their vaccine provider. It is given as 2 doses, at least 28 days apart for people 18 years and over. JYNNEOS® is manufactured by Bavarian Nordic. JYNNEOS® is a modified vaccinia Ankara strain vaccine (MVA-BN) that contains a virus that has been altered so it cannot multiply in the human body.

the person has provided informed consent.

Monkey strong together professional#

a person and their healthcare professional have assessed the possible risks and benefits of receiving the vaccine, and.Where JYNNEOS® is not suitable or not available, ACAM2000™ may be considered for healthy, non-pregnant adults.Īs with any vaccine, vaccination with JYNNEOS® or ACAM2000™ should only take place after: JYNNEOS® is the preferred vaccine for use in Australia based on its safety profile and because it is easier to administer. There are 2 vaccines available for use in Australia: Infection control measures should also be used to contain the spread of mpox. People who have received smallpox vaccines can still catch mpox. If a person is exposed to mpox, receiving a vaccination within 4 days after first exposure to mpox will provide the highest chance of avoiding the disease. Vaccines can be given either before or after a person is exposed to the virus but vaccinating before exposure is recommended for the best protection. There are smallpox vaccines available in Australia that are thought to be effective against mpox. Visit the mpox disease page for all other information about MPX.

General mpox information and case numbers